Astellas Pharma (Japan)
In research, Astellas Pharma (Japan) stands highest in Medicine (#7,068 of 10,443 worldwide) and Health Sciences (#8,746 of 11,982 worldwide), 2022–2025.
- World rank, 2022–2025
- #12,525 of 28,054 · #11,424 all time
- Rank in Japan
- #325 of 1,070
- Research works
- 1.5k ▼ 12% vs 2013–17
- Citations
- 33k 22.4 per fractional work
- Top-10% rate
- 15.5% record average 16.5%
- Open access
- 40% world 28%
What is Astellas Pharma (Japan) known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #7,068 of 10,443 | 17.2% | 77 | #5909 | |
| Health SciencesDomain | #8,746 of 11,982 | 16.7% | 80 | #7815 |
Each strip is that field’s whole ranked pool, with the notch where Astellas Pharma (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 11.1×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 11.1×
- Immunology and Microbiology 4.5×
- Biochemistry, Genetics and Molecular Biology 4.0×
- Medicine 2.5×
- Neuroscience 2.4×
- Mathematics 2.2×
- Chemistry 1.3×
- Veterinary 1.1×
- Economics, Econometrics and Finance 0.8×
- Health Professions 0.6×
- Decision Sciences 0.3×
- Materials Science 0.3×
- Computer Science 0.3×
- Engineering 0.3×
- Environmental Science 0.2×
- Agricultural and Biological Sciences 0.1×
- Dentistry 0.1×
- Psychology 0.1×
- Earth and Planetary Sciences 0.1×
- Nursing 0.1×
- Social Sciences 0.1×
- Physics and Astronomy 0.0×
- Business, Management and Accounting 0.0×
Who are the top researchers at Astellas Pharma (Japan)?
Ranked on the composite score, Tatsuya Maruyama, Mitsuyuki Matsumoto and Toshio Okazaki lead among researchers whose main affiliation is Astellas Pharma (Japan).
- 1 Tatsuya Maruyama Japan · #199,847 worldwide 100 citations · 24 works
- 2 Mitsuyuki Matsumoto Japan · #221,923 worldwide 70 citations · 29 works
- 3 Toshio Okazaki Japan · #773,397 worldwide 27 citations · 19 works
- 4 Hiroyuki Ito Japan · #832,442 worldwide 27 citations · 20 works
- 5 Kentaro Yamanaka Japan · #1,125,430 worldwide 33 citations · 19 works
- 6 Yusuke Yamaguchi Japan · #1,274,641 worldwide 27 citations · 26 works
- 7 Hiroki Shirai Japan · #1,558,951 worldwide 15 citations · 22 works
- 8 Keiji Miyata Japan · #1,573,976 worldwide 10 citations · 21 works
- 9 M. Ikeguchi Japan · #1,579,216 worldwide 0 citations · 27 works
Which keywords describe research at Astellas Pharma (Japan)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Inflammation, Immunotherapy, Heart Failure, Glycosylation, Tumor Microenvironment, Monoclonal Antibodies, Clinical Guidelines and Cancer Therapy.
- Hormone Therapy
- Chronic Kidney Disease
- Glucose Control
- Bayesian Methods
- Gene Therapy
- Autoantibodies
- Chimeric Antigen Receptor
- Transcriptional Regulation
- Cardiovascular Risk
- Regenerative Medicine
- Type 2 Diabetes
- Glycemic Control
- Cell Culture
- Clinical Guidelines
- Monoclonal Antibodies
- Glycosylation
- Chemotherapy
- Cardiovascular Disease
- Cancer
- Immunotherapy
- Inflammation
- Oxidative Stress
- Quality of Life
- Heart Failure
- Cancer Therapy
- Tumor Microenvironment
- Biomarkers
- Therapeutic Antibodies
- Tumor Regression
- Insulin Therapy
- Clinical Trials
- Cancer Immunotherapy
- Lymphoma
- CAR T Cells
- Cancer Treatment
- Breast Cancer
- Pharmacokinetics
- Cardiovascular Outcomes
- Biopharmaceuticals
- Nuclear Receptors
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation11▲ 3.4×34 topics
- Immunotherapy8▲ 7.0×11 topics
- Oxidative Stress7▲ 2.7×21 topics
- Cancer6▲ 3.0×24 topics
- Quality of Life6▲ 2.6×12 topics
- Cardiovascular Disease6▲ 3.4×13 topics
- Heart Failure6▲ 7.9×5 topics
- Chemotherapy5▲ 4.8×11 topics
- Cancer Therapy5▲ 5.6×9 topics
- Glycosylation5▲ 28×3 topics
- Tumor Microenvironment5▲ 7.2×7 topics
- Monoclonal Antibodies5▲ 33×3 topics
- Biomarkers4▲ 4.1×8 topics
- Clinical Guidelines4▲ 9.8×5 topics
- Therapeutic Antibodies4▲ 39×2 topics
- Cell Culture4▲ 23×2 topics
- Tumor Regression4▲ 23×2 topics
- Glycemic Control4▲ 16×4 topics
- Insulin Therapy4▲ 21×3 topics
- Type 2 Diabetes4▲ 11×3 topics
- Clinical Trials4▲ 3.7×10 topics
- Regenerative Medicine4▲ 9.7×3 topics
- Cancer Immunotherapy4▲ 15×2 topics
- Cardiovascular Risk4▲ 7.6×6 topics
- Lymphoma4▲ 15×3 topics
- Transcriptional Regulation4▲ 15×7 topics
- CAR T Cells4▲ 30×1 topic
- Chimeric Antigen Receptor4▲ 30×1 topic
- Cancer Treatment4▲ 9.5×5 topics
- Autoantibodies3▲ 9.1×7 topics
- Breast Cancer3▲ 8.9×6 topics
- Gene Therapy3▲ 11×5 topics
- Pharmacokinetics3▲ 8.0×4 topics
- Bayesian Methods3▲ 41×2 topics
- Cardiovascular Outcomes3▲ 37×1 topic
- Glucose Control3▲ 37×1 topic
- Biopharmaceuticals3▲ 37×3 topics
- Chronic Kidney Disease3▲ 8.1×4 topics
- Nuclear Receptors3▲ 21×5 topics
- Hormone Therapy3▲ 21×3 topics
Which research topics does Astellas Pharma (Japan) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Diabetes Treatment and Management, Statistical Methods in Clinical Trials and Monoclonal and Polyclonal Antibodies Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 4 works
- 2 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 3 works
- 3 Statistical Methods in Clinical Trials Statistics and Probability 3 works
- 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 5 3D Printing in Biomedical Research Biomedical Engineering 2 works
- 6 Drug Solubulity and Delivery Systems Pharmaceutical Science 2 works
- 7 Erythropoietin and Anemia Treatment Hematology 2 works
- 8 Protein purification and stability Molecular Biology 2 works
- 9 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 2 works
- 10 Immune Cell Function and Interaction Immunology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Astellas Pharma (Japan)'s research output changed?
Output in 2018–2022 was 12% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tokyo
- The University of Tokyo
- Tokyo Institute of Technology
- Keio University
- Waseda University
- Tokyo University of Science
- Nihon University
- Hitachi (Japan)
- NTT (Japan)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.